Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cirrhosis influences quality of life after liver transplant

This month's issue of Clinical Transplantation investigates factors influencing change in health-related quality of life after liver transplantation.

News image

fiogf49gjkf04

Dr Begoña Estraviz and colleagues from Spain assessed health-related quality of life in patients following liver transplantation, and the factors associated with health-related quality of life variation.

The team collected sociodemographic and clinical data for 60 consecutive patients activated for liver transplantation in a single hospital.

Patients were classified according to the severity of the cirrhosis, and disease etiology, such as alcoholic cirrhosis, viral cirrhosis, cholestatic diseases, and hepatocarcinoma.

6-months post-transplant, the scores on most domains remained below 50
Clinical Transplantation

Health-related quality of life was assessed by 3 different questionnaires.

The investigative team used the Health Survey Short Form 36, the Hospital Anxiety and Depression Scale, and a specific-symptom questionnaire.

Questionnaires were completed during the pre-operative period and 6 months after transplantation.

The team found in the pre-operative period, patients with Child A had higher mean levels of health-related quality of life than did those in other groups.

At 6 months following transplantation, there were no significant differences among the groups.

The investigators noted that this was largely because gains obtained by patients with Child B and C were much greater than those attained by patients with Child A.

The team found across the 4 etiological groups, there were significant differences in all domains of the 3 questionnaires.

The exceptions were bodily pain scored using the Health Survey Short Form-36, and anxiety as measured by the Hospital Anxiety and Depression Scale prior to transplantation.

The investigators noted that this was because patients with hepatocarcinoma had much better health-related quality of life.

The team found after transplantation, there were no differences because patients with viral and alcohol-induced cirrhosis achieved greater gains with respect to the neoplastic group.

During the pre-operative period, the scores for all areas of the Short Form-36 and for all groups were below the general population normalized score of 50.

The team reported that the only groups not below the general population normalized score were patients with Child class A, and those affected with hepatocarcinoma.

The investigators observed that 6-months post-transplantation, the scores on most of the domains remained below 50.

However, the team found that certain mental areas in which higher scores were attained in certain mental areas.

Dr Estraviz's team concluded, "Health-related quality of life is influenced by the severity and etiology of cirrhosis—patients with Child class C and those with alcoholic or viral cirrhosis have the poorest quality of life."

"There were no differences observed among the groups after the transplantation."

"The patients with the lowest health-related quality of life prior to surgery demonstrated greater gains in health-related quality of life associated with liver transplantation."

Clin Transplant2007: 21(4): 481-99
17 September 2007

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 21 February 2018 
Management of hemorrhoids in the USA
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us